

NEXT SCIENCE®

**Next Science Limited
2022 Annual General Meeting
Friday, 27 May 2022**

Chair & Managing Director Addresses

Chair Address

Ladies and gentlemen,

My name is Mark Compton and I am delighted to join with fellow shareholders today in my first AGM as Chair of our company.

Let me begin by reaffirming our vision and purpose. At Next Science, we are driven by a clear vision to heal patients and save lives by providing solutions to prevent, treat and eliminate biofilm-based bacteria.

Next Science has a unique opportunity. We can, and are, making a real difference to the lives of people across the globe with our unique X BIO™ platform technology and suite of patented products. Our people (including the Board) are committed to this purpose, and we are dedicated in pursuing our purpose of making our products available worldwide.

I am pleased to report that in 2021 we achieved record sales with contributions from across all Next Science in-market products. We made good progress in executing our strategy to accelerate market adoption of our products despite widespread disruptions resulting from the Covid-19 pandemic including significant reductions in the number of surgical procedures conducted in our principal market of the United States, in addition to the very restricted access to hospitals, clinics and the like to be able to speak to clinicians about our technology and products. We hope that as restrictions lift this access will improve and allow our people to communicate directly with current and potential end-users.

The securing of FDA approval in April 2021, for XPERIENCE™ our advanced (“leave-in”) surgical irrigation solution, was an important milestone. The Board continues to believe that XPERIENCE offers Next Science the greatest product opportunity to date with the potential to materially accelerate the Company’s revenue growth.

Optimising our distribution partnerships as well as our manufacturing relationships was a significant focus during 2021 and in early 2022. The Company was able to convert a legal complaint from our longstanding distribution partner, Zimmer Inc. over commercialisation and distribution rights to XPERIENCE, into an improved and enhanced relationship.

This rejuvenated partnership encompasses a new US distribution arrangement for XPERIENCE as well as a refreshed Bactisure™ distribution arrangement. The new US distribution arrangement for XPERIENCE means Zimmer’s specialist joint replacement sales team will be selling a white label version of XPERIENCE.

In the second half of 2021, we established a new exclusive distribution relationship with TELA Bio Inc, for the sale of XPERIENCE in the US plastic surgery market. TELA Bio is a NASDAQ listed company focused on commercial stage medical technologies in the soft tissue reconstruction market.

Combined with our contracted commission sales force primarily focused on the orthopaedic market, we are well placed to generate an uplift in the representation of Next Science's products to the US market.

To support anticipated sales growth, we supplemented our manufacturing capacity and diversified our supply chains by broadening our relationship with Holopak in Germany to include XPERIENCE. We also focused on developing all our manufacturing relationships to ensure they continue to meet our business requirements as we grow.

We successfully transitioned BlastX™ distribution back to Next Science creating opportunities for us to sell to a wider customer set. Customer responses have so far been positive, enabling us to expand the BlastX customer base under the direct sales model. As we move through 2022, we are expanding our BlastX coverage into acute care using our direct sales network.

With the US healthcare sector playing such an important role for our business and the majority of our staff being located in Jacksonville, Florida we were delighted that travel restrictions eased during 2021 allowing our Managing Director, Judith Mitchell, to temporarily relocate to the US in October.

As announced to the market this morning, Judy has advised the Board that having been on the ground in the US for the last six months, her assessment is that the business would benefit from the CEO being located in the US. Judy also advised the Board that she was not, for personal reasons, able to make a long-term commitment to reside in the US and for this reason, intends to retire from Next Science some time before 30 June 2023 and when mutually convenient.

The Board has engaged in deep discussions with Judy regarding her assessment and the Company's medium to long term strategic plans. These discussions have made clear that the US will continue to be our main focus for the foreseeable future. Given the scale of the Company's opportunities in the US, the Board supports Judy's assessment that the business needs to be led from the US.

The ASX listing of the Company, governance plus financial control centre and decision-making base of the Group will remain in Sydney under the direction and control of the Board.

All of the Directors, Judy included, are comfortable that the process and timing of the relocation of the leadership team are aligned with our current opportunities for expansive growth in the US market and that patients, healthcare professionals, employees, partners and shareholders will all benefit from the move.

The Board is greatly appreciative to Judy for the time she has spent on the ground in the US, her indefatigable work across time zones and geographies and her commitment to remain in the US to allow a smooth and orderly transition to a new CEO. Judy will continue to lead the team whilst based in the Jacksonville offices until a successful transition to a new CEO has been achieved. Judy remains a significant and very supportive shareholder in the Company.

On behalf of the Board and shareholders I would like to thank Judy for her constructive and company-focused approach to this leadership transition and her exemplary contribution to Next Science. Judy successfully led the Company's transition from its pre-commercial research foundations to the ASX IPO and current move into an exciting commercial phase and US expansion. We recognise and thank her for her leadership, dedication and tireless commitment and wish her well for the future. Thank you, Judy.

With the emerging recovery in the US surgery market, there is much to be excited about for Next Science in 2022.

We strengthened our balance sheet earlier this year, successfully completing a placement of new shares to institutional and sophisticated investors supplemented by a share purchase plan raising, in total, A\$14.9M. These funds ensure we have the working capital to support our growth plans.

We expect to benefit in 2022 from our significantly expanded sales coverage in the US for XPERIENCE and SurgX™ as well as the launch in the US of TorrentX under the TridentX™ Wound Wash brand and the launches of XPERIENCE and BlastX in Australia and New Zealand.

The Company will continue to be focused throughout the remainder of 2022 on continuing to expand doctor and patient access to our suite of patented products and accelerate broader market adoption, as we pursue our purpose of healing people and saving lives.

On behalf of the Board, I would like to thank all shareholders for your continued loyalty, support and dedication. Thank you to my fellow Directors for your commitment, hard work and wise counsel dedicated to governing on behalf of shareholders and in their best interests, to the executive team and all staff of Next Science for delivering on our purpose of saving lives by raising the standard of care through our patented XBio technology platform and finally to the healthcare professionals who have chosen to trust in Next Science's technology and products. Together we can heal patients and save lives.

I will now hand to Judy who will take you through the highlights of our progress in 2021 and its continuation in the first half of this year.

Managing Director's Address

Thank you Chair and good morning everyone.

Good morning to our shareholders, directors, staff members and our business partners who are joining us today. Welcome.

This morning, we would like to review our progress over 2021 and then discuss the growth strategies and market opportunities we are executing for our business moving forward.

As you know, we are the company which is developing, patenting and commercialising answers for the serious and damaging issues biofilms can cause in human health. We have developed our proprietary XBio™ technology into a series of new products used by health care providers either in the prevention of infection or the treatment of infected spaces where we can physically touch the infection such as chronic wounds and prosthetic joint infection.

2021 was a year of growth and positive developments as we executed our strategy to build market awareness and adoption of our products. Our key milestones were delivering 160% growth in revenue, expanding the US product base to 4, first product sales in Europe, bringing a specialist distribution partner for Plastic Surgery and continuing to expand our patent data base. You can see from slide 10, product revenues are on the increase.

Let's talk about our commercial progress and in particular, the role we are directly playing alongside our distribution partners.

In 2021, we started the first quarter, with only 1 direct product for sale by Next Science in the US market – that product was SurgX™. At the same time, our distribution partner, Zimmer

Biomet, expanded our global presence by taking our surgical lavage product, Bactisure™, to Europe and the UK, making that product available in more than 60% of the developed markets globally and we were ending an unsuccessful partnership with 3M.

As we moved into quarter 2, we took back BlastX™ from 3M. We also received FDA Clearance for XPERIENCE™ and launched the product in the US market. These moves were the foundations for long term growth. They also provided us with 3 products for direct sales in the US.

In the second half of the year, we continued to build the business for scale and sustained success. We brought TELA Bio Inc on board as a US distributor of XPERIENCE™ in the plastic surgery market with their own TELA Bio brand - Site Guard Surgical Solution. So, we finished the year with 3 direct products in the US and 2 major distribution partners. We have made further progress in executing our strategy in the first half of 2022 with ongoing growth compared to the prior corresponding period and we also have further recovery potential as the surgery backlog caused by COVID unwinds.

In June of this year, we will ship-TridentX™ a wound wash incorporating the XBio technology, to Triad Life Sciences, Inc, to start our 3rd distribution relationship within the US market (Triad is now owned by Convatec, the market leader in antimicrobial bandages).

This brings the products distributed by partners in the US market to 3, alongside the 3 products sold directly through Next Science (XPERIENCE™, BlastX™ and SurgX™). The strategy to partner with established and successful market leaders amplifies our reach and accelerates adoption.

You can see how we have been steadily building our product portfolio and distribution arrangements. In summary, over the last 18 months, we have moved our partnerships and distributorships from 2 to 5 and are expanding our direct sales product offering to 3 products. All of these actions are expected to positively impact our revenue growth in 2022 and beyond.

The second half of 2022 promises the delivery of further significant milestones for Next Science.

Zimmer Biomet, a major player in the US healthcare market, is going to begin distributing a Zimmer Biomet branded version of XPERIENCE™ in the US. Plans are well underway for the commercial launch. This will also bring our distributor partner products in the US to 4.

As announced last week, the distribution of BLASTX™ in Australia is going to begin in the second half through our new distribution partner, Oraderm, a joint venture between Douglas Pharma of New Zealand and Arrotex (a major pharmaceutical company in Australia).

So, with these key partnerships and products in place, what else do we need to do to support Next Science's long-term growth? As we have advised previously, we will be supporting our key products – XPERIENCE™, SurgX™ and BlastX™ – with clinical studies. There is very good news on this front. We are pleased to report our first two case study series of XPERIENCE™ will be published in the next two months. As you know, XPERIENCE™ is our leave-in surgical wash designed to prevent surgical site infections.

One case study relates to the use of XPERIENCE™ in surgeries performed at a US Ambulatory Surgery Center (ASC) on 400 patients. The study data shows zero post operative infections. We safely eliminated all of the biofilm and harmful bacteria that cause infections. The other case study looks at the use of XPERIENCE™ in a US community hospital setting of 500 patients. Again, the study data shows zero post operative infections.

These are compelling study results, which will support our commercialisation efforts for XPERIENCE™.

We also have a SurgX™ study at Jack Hughston Memorial Hospital, Georgia, being submitted for publication, reporting on 360 patients with zero skin level infections post-surgery. This data is also compelling and key to supporting our growth and commercial success.

At Next Science, we are committed to driving a breadth of clinical evidence, predominantly in vivo, supplemented with in vitro and animal studies, to build the necessary evidence to support our products. Our goal is to ultimately become the standard of care in the battle to control bacterial infections and biofilms.

Ladies and gentlemen, as you have heard, the US is our main focus and will continue to be our main focus for the foreseeable future. This is because the US healthcare market is well established, large and well-funded. Whilst the US healthcare market is challenging in terms of commercialisation and regulatory requirements, it is a market with real demand for our products and one in which we must and will be successful.

I have been on the ground in the US since October of 2021. It has become clear to me that the business needs to be led from the US, at this time, not Australia. I have had constructive discussions with the Board, and they support my assessment.

I have enjoyed my time here in Jacksonville but it isn't somewhere I wish to make my permanent home, at this time in my life. Therefore, as announced this morning, my intention is to retire from Next Science. I will continue to lead the team based out of the Jacksonville offices until the appointment of a US based Group CEO has been made and my presence on the ground is no longer necessary. At that point, I will return to Sydney to enjoy being a long-term shareholder and supporter. This managed process will allow a smooth and orderly transition. I can assure you that in the meantime, I will remain fully focused and driven to execute the company's growth strategy.

The ASX listing of the company, governance plus financial control centre and decision-making base of the Group will remain in Sydney under the direction and control of the Board of Directors.

All of the Directors, myself included, are comfortable that the timing of the relocation of the leadership team is aligned with our current opportunities for expansive growth in the US market and that patients, healthcare professionals, employees, partners and shareholders will all benefit from the move.

I would like to take this opportunity to thank our Chair, our Board, and our shareholders for their support this year, and a huge shout out to the outstanding employees of Next Science who all come to work aligned with our mission to heal people and save lives. We value everything you do for us every day.

I will now hand back to the Chair.

Approved for release by the Board of Directors